SNTI
Senti Biosciences Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
Senti Biosciences Holdings, Inc.
Expected move
InputsNext report
Last report
—
Largest filed tie
13F top-10 QoQ
Top fund weight
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Mar 27 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 27 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
0.00%
SNTI weight · VTI
Largest filed tie
—
Senti Biosciences Holdings, Inc.
0.17
−0.01 · −3.20%
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Senti Biosciences Holdings, Inc..
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Senti Biosciences Holdings, Inc..
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $591,254 | 47.55% | new |
| Geodeindex-like | $205,778 | 16.55% | new |
| Citadel | $117,810 | 9.48% | new |
| Vanguard Fiduciary Trustindex-like | $100,312 | 8.07% | new |
| Jane Street | $57,783 | 4.65% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Vanguardindex-like | $591,254 | 47.55% | new |
| Geodeindex-like | $205,778 | 16.55% | new |
| Citadel | $117,810 | 9.48% | new |
| Vanguard Fiduciary Trustindex-like | $100,312 | 8.07% | new |
| Jane Street | $57,783 | 4.65% | new |
—
—
—
Expected move
No implied move.